General Research
Model: human
Hydrogen gas (XEN) inhalation ameliorates airway inflammation in asthma and COPD patients
Simplified Version Available
Breathe Easy: How Hydrogen Gas Inhalation Can Help Asthma and COPD Patients
Hydrogen gas inhalation has been shown to reduce airway inflammation in people with asthma and COPD, offering new hope for managing symptoms and improving quality of life. This treatment has the potential to revolutionize the way we treat these conditions. More research is needed, but the results are promising.
Read Simplified ArticleAbstract
Publish Year 2020 Country China Rank Positive Journal QJM Primary Topic Lung Secondary TopicChronic Obstructive Pulmonary Disease Model Human Tertiary TopicInflammation Vehicle Gas pH N/A Application Inhalation Comparison Complement
Background
Methods: 2.4% hydrogen containing steam mixed gas (XEN) was inhaled once for 45 minutes in 10 patients with asthma and 10 patients with COPD. The levels of granulocyte-macrophage colony stimulating factor (GM-CSF), interferon-γ (IFNγ), interleukin-1β (IL-1β), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), et al. in peripheral blood and exhaled breath condensate (EBC) before and after 'XEN' inhalation were measured.
Methods
Results: 45 minutes 'XEN' inhalation once decreased monocyte chemotactic protein 1 (MCP1) level in both COPD (564.70 to 451.51pg/mL, P = 0.019) and asthma (386.39 to 332.76 pg/mL, P = 0.033) group, while decreased IL-8 level only in asthma group (5.25 to 4.49pg/mL, P = 0.023). The level of EBC soluble cluster of differentiation-40 ligand (sCD40L) in COPD group increased after inhalation (1.07 to 1.16pg/mL, P = 0.031), while IL-4 and IL-6 levels in EBC were significantly lower after inhalation in the COPD (0.80 to 0.64pg/mL, P = 0.025) and asthma (0.06 to 0.05pg/mL, P = 0.007) group respectively. Conclusions: A single inhalation of hydrogen for 45 minitues attenuated inflammatory status in airways in patients with asthma and COPD.